MIRA Pharmaceuticals (NASDAQ:MIRA) | Finanzwire

Basculer en Français

8585	Companies
139145	Keywords
75216	Articles
74321	Press releases

Home
Companies
MIRA Pharmaceuticals

BRIEF

published on 03/24/2025 at 12:35, 7 days 1 hour ago

MIRA Pharmaceuticals to Acquire SKNY, Bolstering Drug Development

Smoking Cessation MIRA Pharmaceuticals Pharmaceutical Acquisition Weight Loss Drugs SKNY-1 Development
PRESS RELEASE

published on 03/24/2025 at 12:30, 7 days 1 hour ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
MIRA acquires SKNY Pharmaceuticals, enhancing pipeline with next-gen oral therapeutic for obesity and smoking. Strategic move to address leading causes of preventable death

Acquisition Smoking Obesity MIRA Pharmaceuticals SKNY Pharmaceuticals
BRIEF

published on 03/13/2025 at 13:05, 18 days ago

MIRA Pharmaceuticals Enhances Ketamir-2 with Topical Pain Treatment

Pain Management Ketamir-2 Neuropathic Pain Topical Treatment Inflammatory Pain
PRESS RELEASE

published on 03/13/2025 at 13:00, 18 days ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
MIRA Pharmaceuticals introduces topical Ketamir-2 for neuropathic and inflammatory pain, expanding pain management portfolio with innovative targeted approach

MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Treatment Inflammatory Pain
BRIEF

published on 03/04/2025 at 14:05, 26 days 23 hours ago

MIRA Pharmaceuticals Advances with Phase 1 Trial for Ketamir-2

Clinical Study Pharmaceutical Development Neuropathic Pain Ketamir-2 Trial Therapeutic Innovation
PRESS RELEASE

published on 03/04/2025 at 14:00, 26 days 23 hours ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
MIRA Pharmaceuticals, Inc. announces Phase 1 clinical trial initiation for Ketamir-2, a novel oral ketamine analog targeting neuropathic pain, in Israel. Study aims to evaluate safety, tolerability, and pharmacokinetics

Phase 1 Clinical Trial Israel MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 12/19/2024 at 15:05, 3 months 11 days ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA

Ketamir-2 NMDA Receptor Neuropathic Pain FDA IND Submission Phase I Clinical Trials
PRESS RELEASE

published on 12/19/2024 at 15:00, 3 months 11 days ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
MIRA Pharmaceuticals submits IND application for novel oral ketamine analog Ketamir-2 to FDA, targeting neuropathic pain. Phase I trials planned to start in 2025

FDA IND Application MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 12/10/2024 at 14:35, 3 months 20 days ago

MIRA Pharmaceuticals Advances Towards Clinical Trials with Ketamir-2

Clinical Trials Ketamir-2 Neuropathic Pain Safety Profile Pharmaceutical Milestone
PRESS RELEASE

published on 12/10/2024 at 14:30, 3 months 20 days ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
MIRA Pharmaceuticals successfully completes preclinical safety program for Ketamir-2, paving the way for clinical trials in neuropathic pain. Strategic focus on advancing innovative, safe treatments for patients

Clinical Trials Drug Development MIRA Pharmaceuticals Neuropathic Pain Preclinical Safety Program

1 2 ... 4

Accesswire

Published on 03/31/2025 at 13:00, 36 minutes ago

Snipp Interactive Announces US$800,000 Renewal with Leading Roofing Products Company to Enhance their Channel Loyalty Program
Published on 03/31/2025 at 13:00, 36 minutes ago

Aclara Advances EIA Evaluation Process for the Penco Module
Published on 03/31/2025 at 13:00, 36 minutes ago

Gold Terra Announces Funding Package of C$4,400,000 with support from Osisko Gold Royalties
Published on 03/31/2025 at 13:00, 36 minutes ago

Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
Published on 03/31/2025 at 13:00, 36 minutes ago

Electrovaya Announces Results of Annual Meeting of Shareholders

View all ACCESSWIRE

EQS Group

Published on 03/31/2025 at 13:25, 10 minutes ago

Dalata Hotel Group PLC: NOA-Notice of AGM
Published on 03/31/2025 at 13:00, 35 minutes ago

Personnel: Commercial Director of HOWOGE, Katharina Greis, to leave the company
Published on 03/31/2025 at 13:00, 35 minutes ago

Total Voting Rights
Published on 03/31/2025 at 12:45, 50 minutes ago

IBU-tec and Wanhua Chemical agree on development partnership for battery materials
Published on 03/31/2025 at 12:24, 1 hour 11 minutes ago

Dalata Hotel Group PLC: Form 8.1 (c) & (d)(i)

Les Echos

Published on 03/31/2025 at 08:45, 4 hours 51 minutes ago

Performing sustainably: in 2024, Air Liquide has progressed on all extra-nancial indicators of its ADVANCE plan
Published on 03/28/2025 at 22:00, 2 days 15 hours ago

Biophytis announces the settlement and delivery of its €2.6 million private placement
Published on 03/28/2025 at 17:45, 2 days 19 hours ago

Availability of the 2024 Universal Registration Document including the Annual Financial Report
Published on 03/28/2025 at 17:45, 2 days 19 hours ago

Publication of Carrefour's 2024 Universal Registration Document
Published on 03/28/2025 at 17:45, 2 days 19 hours ago

Covivio - Conditions of availability of preparatory documents to the Combined Ordinary and Extraordinary General Meeting of 17 April 2025

View all LES ECHOS COMFI WIRE